Xi Zou

Xi Zou

Auto-generated profile, based on publicly available information

Xi Zou

The Third Affiliated Hospital of Zhejiang Chinese Medical University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
XLXing Liu
Xing Liu
YSYidan Shao
Yidan Shao
YLYunjiang Li
Yunjiang Li
ZCZuhua Chen
Zuhua Chen
TSTingting Shi
Tingting Shi
XPXuwang Pan
Xuwang Pan
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world, mainly because of its powerful pro-connective tissue proliferation matrix and immunosuppressive tumor microenvironment (TME), which promote tumor progression and metastasis. In addition, the extracellular matrix leads to vascular collapse, increased interstitial fluid pressure, and obstruction of lymphatic return, thereby hindering effective drug delivery, deep penetration, and immune cell infiltration. Therefore, reshaping the TME to enhance tumor perfusion, increase deep drug penetration, and reverse immune suppression has become a key therapeutic strategy. Traditional therapies for PDAC, including surgery, radiation, and chemotherapy, face significant limitations. Surgery is challenging due to tumor location and growth, while chemotherapy and radiation are hindered by the dense extracellular matrix and immunosuppressive TME. In recent years, the advancement of nanotechnology has provided new opportunities to improve drug efficacy. Nanoscale drug delivery systems (NDDSs) provide several advantages, including improved drug stability in vivo, enhanced tumor penetration, and reduced systemic toxicity. However, the clinical translation of nanotechnology in PDAC therapy faces several challenges. These include the need for precise targeting and control over drug release, potential immune responses to the nanocarriers, and the scalability and cost-effectiveness of production. This article provides an overview of the latest nanobased methods for achieving better therapeutic outcomes and overcoming drug resistance. We pay special attention to TME-targeted therapy in the context of PDAC, discuss the advantages and limitations of current strategies, and emphasize promising new developments. By emphasizing the enormous potential of NDDSs in improving the treatment outcomes of patients with PDAC, while critically discussing the limitations of traditional therapies and the challenges faced by nanotechnology in achieving clinical breakthroughs, our review paves the way for future research in this rapidly developing field.

29 September 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
XZXi Zou
Xi Zou
YKYunling Ke
Yunling Ke
YSYidan Shao
Yidan Shao
SLShourong Liu
Shourong Liu
TSTingting Shi
Tingting Shi
Liver fibrosis is a key intermediate stage in the progression of chronic liver disease to end-stage liver cirrhosis. Mortality rises exponentially once it reaches decompensated liver disease. In a healthy liver microenvironment, hepatocytes, Kupffer cells, hepatic stellate cells (HSCs), liver sinusoidal endothelial cells, and other cells interact with extracellular matrix (ECM) to maintain cell stability and liver function. Different types of liver injury (such as viral hepatitis and alcoholic liver injury) can cause liver fibrosis. Liver injury signals activate Kupffer cells and recruit immune cells, leading to liver inflammation. This inflammation, together with liver injury, stimulates the activation of HSCs. Activated HSCs migrate to injury sites and secrete ECM. The ECM increase and stiffening contribute to fibrosis. Microenvironment changes alter cell phenotypesperpetuating HSC activation. This article explores liver fibrosis mechanisms, reviews cellular and microenvironmental changes, summarizes fibrosis characteristics, and provides insights for clinical treatment. Cite this article as: Zou X, Ke Y, Shao Y, Liu S, Shi T. Liver fibrosis: interactions between cells and microenvironments. Turk J Gastroenterol. 2025;36(11):711-722.

29 September 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
XZXi Zou
Xi Zou
YKYunling Ke
Yunling Ke
YSYidan Shao
Yidan Shao
SLShourong Liu
Shourong Liu
TSTingting Shi
Tingting Shi
Liver fibrosis is a key intermediate stage in the progression of chronic liver disease to end-stage liver cirrhosis. Mortality rises expo nentially once it reaches decompensated liver disease. In a healthy liver microenvironment, hepatocytes, Kupffer cells, hepatic stellate cells (HSCs), liver sinusoidal endothelial cells, and other cells interact with extracellular matrix (ECM) to maintain cell stability and liver function. Different types of liver injury (such as viral hepatitis and alcoholic liver injury) can cause liver fibrosis. Liver injury signals acti vate Kupffer cells and recruit immune cells, leading to liver inflammation. This inflammation, together with liver injury, stimulates the activation of HSCs. Activated HSCs migrate to injury sites and secrete ECM. The ECM increase and stiffening contribute to fibrosis. Microenvironment changes alter cell phenotypes, perpetuating HSC activation. This article explores liver fibrosis mechanisms, reviews cellular and microenvironmental changes, summarizes fibrosis characteristics, and provides insights for clinical treatment. Cite this article as: Zou X, Ke Y, Shao Y, Liu S, Shi T. Liver fibrosis: interactions between cells and microenvironments. Turk J Gastroenterol. Published online September 29, 2025. doi:10.5152/tjg.2025.25313.

1 January 2025 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
XZXi Zou
Xi Zou
WCWei Chen
Wei Chen
YSYidan Shao
Yidan Shao
TSTingting Shi
Tingting Shi
YKYunling Ke
Yunling Ke
Objective: Investigating the antialcoholic liver injury properties of Rabdosia rubescens and its effect on the expression of CYP7A1 and levels of autophagy. Materials and Methods: Male C57BL/6 mice were randomly divided into three groups, namely, the control group (Lieber–DeCarli standard diet), model group (Lieber–DeCarli ethanol diet), and treatment group ( Rabdosia rubescens at concentrations of 50 mg/kg, 100 mg/kg, and 200 mg/kg). The mice were fed their respective diets for 10 days, with the treatment group receiving the corresponding concentration of Rabdosia rubescens . On the 11th day, all the mice except those in the control group were given 30% EtOH. Nine hours later, the mice were sacrificed and their blood serum and liver tissue were collected for analysis. The effect of Rabdosia rubescens on alcohol‐induced liver damage was evaluated by testing serum biochemical indicators, liver bile acid content, liver tissue histopathological changes, liver LC3 and p62 immunohistochemical staining, liver inflammatory factors, and CYP7A1, SREBP, FAS, LC3, Beclin‐1, ATG7, and p62 expressions. Results: Compared with the model group, Rabdosia rubescens was found to significantly reduce the levels of ALT, AST, TG, TC, and TBA in the serum of mice with alcoholic liver injury ( p < 0.05 or p < 0.01). Rabdosia rubescens was found to significantly reduce the level of apoptosis in H&E‐stained liver tissue sections. Rabdosia rubescens also significantly reduced the levels of TNF‐α and IL‐1β in the livers of mice ( p < 0.001). Rabdosia rubescens was found to induce the expression of LC3, Beclin‐1, and ATG7 proteins and mRNA, while inhibiting the expression of CYP7A1, SREBP, FAS, and p62 proteins and mRNA ( p < 0.05 or p < 0.01). Conclusion: Rabdosia rubescens has been shown to relieve alcohol‐induced liver damage in mice by reducing levels of CYP7A1, alleviating cholestasis and reducing inflammation. It can also reduce alcohol‐induced liver damage by decreasing fat synthesis and inducing autophagy.